Robert Nelsen - Net Worth and Insider Trading
Robert Nelsen Net Worth
The estimated net worth of Robert Nelsen is at least $1.6 Billion dollars as of 2024-04-27. Robert Nelsen is the Director, 10% Owner of Karuna Therapeutics Inc and owns about 3,362,872 shares of Karuna Therapeutics Inc (KRTX) stock worth over $1.1 Billion. Robert Nelsen is the Director, 10% Owner of Vir Biotechnology Inc and owns about 28,666,663 shares of Vir Biotechnology Inc (VIR) stock worth over $236 Million. Robert Nelsen is also the Director, 10% Owner of Juno Therapeutics Inc and owns about 1,097,015 shares of Juno Therapeutics Inc (JUNO) stock worth over $95 Million. Besides these, Robert Nelsen also holds Sana Biotechnology Inc (SANA) , Prime Medicine Inc (PRME) , Alnylam Pharmaceuticals Inc (ALNY) , Fate Therapeutics Inc (FATE) , Agios Pharmaceuticals Inc (AGIO) , Syros Pharmaceuticals Inc (SYRS) . Details can be seen in Robert Nelsen's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Robert Nelsen has not made any transactions after 2024-02-15 and currently still holds the listed stock(s).
Transaction Summary of Robert Nelsen
Robert Nelsen Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Robert Nelsen owns 40 companies in total, including Codiak BioSciences Inc (CDAKQ) , Metacrine Inc (MTCR) , and Unity Biotechnology Inc (UBX) among others .
Click here to see the complete history of Robert Nelsen’s form 4 insider trades.
Insider Ownership Summary of Robert Nelsen
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
CDAKQ | Codiak BioSciences Inc | 2020-10-13 | 10 percent owner |
MTCR | Metacrine Inc | 2020-09-15 | 10 percent owner |
UBX | Unity Biotechnology Inc | 2020-06-18 | director |
KRTX | Karuna Therapeutics Inc | 2019-07-02 | director & 10 percent owner |
DNLI | Denali Therapeutics Inc | 2019-08-08 | director & 10 percent owner |
VIR | Vir Biotechnology Inc | 2021-03-30 | director & 10 percent owner |
BEAM | Beam Therapeutics Inc | 2020-02-05 | director & 10 percent owner |
SYRS | Syros Pharmaceuticals Inc | 2019-03-07 | 10 percent owner |
FIXX | Homology Medicines Inc | 2018-03-27 | 10 percent owner |
SNNAQ | Sienna Biopharmaceuticals Inc | 2019-02-22 | 10 percent owner |
GOSS | Gossamer Bio Inc | 2019-02-07 | 10 percent owner |
TWST | Twist Bioscience Corp | 2018-11-02 | 10 percent owner |
SRRK | Scholar Rock Holding Corp | 2018-05-23 | 10 percent owner |
PULM | Pulmatrix Inc | 2018-04-03 | other: Former 10% owner |
JUNO | Juno Therapeutics Inc | 2018-03-05 | director |
QTRX | Quanterix Corp | 2020-11-20 | 10 percent owner |
AGIO | Agios Pharmaceuticals Inc | 2017-03-06 | director & 10 percent owner |
XCOMQ | Xtera Communications Inc | 2016-10-11 | 10 percent owner |
PI | Impinj Inc | 2016-07-20 | 10 percent owner |
PZRXQ | PhaseRx Inc | 2016-05-23 | 10 percent owner |
SAGE | Sage Therapeutics Inc | 2015-01-14 | director & 10 percent owner |
IOTS | Adesto Technologies Corp | 2015-10-30 | 10 percent owner |
BLPH | Bellerophon Therapeutics Inc | 2015-02-13 | director & 10 percent owner |
AKAOQ | Achaogen Inc | 2014-03-17 | 10 percent owner |
FATE | Fate Therapeutics Inc | 2013-10-04 | director & 10 percent owner |
BLUE | bluebird bio Inc | 2013-06-18 | 10 percent owner |
NGSX | NeurogesX Inc | 2012-06-07 | director & 10 percent owner |
CYCC | Cyclacel Pharmaceuticals Inc | 2005-06-17 | director & 10 percent owner |
ALNY | Alnylam Pharmaceuticals Inc | 2004-05-27 | 10 percent owner |
ILMN | Illumina Inc | 2003-05-27 | director |
MASS | 908 Devices Inc | 2020-12-17 | 10 percent owner |
ERAS | Erasca Inc | 2021-07-15 | 10 percent owner |
SANA | Sana Biotechnology Inc | 2024-02-08 | director |
LYEL | Lyell Immunopharma Inc | 2021-06-16 | director & 10 percent owner |
VERV | Verve Therapeutics Inc | 2021-06-16 | 10 percent owner |
REVHU | Revolution Healthcare Acquisition Corp | 2021-03-17 | director |
DALS | DA32 Life Science Tech Acquisition Corp | 2021-07-27 | 10 percent owner |
REVH | Revolution Healthcare Acquisition Corp | 2021-03-17 | director |
PRME | Prime Medicine Inc | 2024-02-15 | director & 10 percent owner |
NMRA | Neumora Therapeutics Inc | 2023-09-14 | 10 percent owner |
Robert Nelsen Latest Holdings Summary
Robert Nelsen currently owns a total of 9 stocks. Among these stocks, Robert Nelsen owns 3,362,872 shares of Karuna Therapeutics Inc (KRTX) as of July 2, 2019, with a value of $1.1 Billion and a weighting of 67.39%. Robert Nelsen owns 28,666,663 shares of Vir Biotechnology Inc (VIR) as of October 16, 2019, with a value of $236 Million and a weighting of 14.33%. Robert Nelsen also owns 1,097,015 shares of Juno Therapeutics Inc (JUNO) as of December 18, 2014, with a value of $95 Million and a weighting of 5.8%. The other 6 stocks Sana Biotechnology Inc (SANA) , Prime Medicine Inc (PRME) , Alnylam Pharmaceuticals Inc (ALNY) , Fate Therapeutics Inc (FATE) , Agios Pharmaceuticals Inc (AGIO) , Syros Pharmaceuticals Inc (SYRS) have a combined weighting of 12.48% among all his current holdings.
Latest Holdings of Robert Nelsen
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
KRTX | Karuna Therapeutics Inc | 2019-07-02 | 3,362,872 | 329.83 | 1,109,176,072 |
VIR | Vir Biotechnology Inc | 2019-10-16 | 28,666,663 | 8.23 | 235,926,636 |
JUNO | Juno Therapeutics Inc | 2014-12-18 | 1,097,015 | 86.96 | 95,396,424 |
SANA | Sana Biotechnology Inc | 2024-02-08 | 10,315,103 | 8.72 | 89,947,698 |
PRME | Prime Medicine Inc | 2024-02-15 | 15,472,674 | 4.43 | 68,466,582 |
ALNY | Alnylam Pharmaceuticals Inc | 2004-05-27 | 222,500 | 143.31 | 31,886,475 |
FATE | Fate Therapeutics Inc | 2013-10-04 | 2,473,188 | 3.80 | 9,398,114 |
AGIO | Agios Pharmaceuticals Inc | 2017-03-06 | 109,230 | 31.49 | 3,439,653 |
SYRS | Syros Pharmaceuticals Inc | 2016-07-06 | 463,714 | 5.04 | 2,337,119 |
Holding Weightings of Robert Nelsen
Robert Nelsen Form 4 Trading Tracker
According to the SEC Form 4 filings, Robert Nelsen has made a total of 1 transactions in Karuna Therapeutics Inc (KRTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Karuna Therapeutics Inc is the acquisition of 200,000 shares on July 2, 2019, which cost Robert Nelsen around $3 Million.
According to the SEC Form 4 filings, Robert Nelsen has made a total of 1 transactions in Vir Biotechnology Inc (VIR) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Vir Biotechnology Inc is the acquisition of 1,000,000 shares on October 16, 2019, which cost Robert Nelsen around $20 Million.
According to the SEC Form 4 filings, Robert Nelsen has made a total of 0 transactions in Juno Therapeutics Inc (JUNO) over the past 5 years. The most-recent trade in Juno Therapeutics Inc is the sale of 0 shares on December 18, 2014, which brought Robert Nelsen around $0.
More details on Robert Nelsen's insider transactions can be found in the Insider Trading History of Robert Nelsen table.Insider Trading History of Robert Nelsen
- 1
Robert Nelsen Trading Performance
GuruFocus tracks the stock performance after each of Robert Nelsen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Robert Nelsen is -6.84%. GuruFocus also compares Robert Nelsen's trading performance to market benchmark return within the same time period. The performance of stocks bought by Robert Nelsen within 3 months outperforms 2 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Robert Nelsen's insider trading performs compared to the benchmark.
Performance of Robert Nelsen
Average Return
97.39%
Outperforming Transactions
60%
1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
---|---|---|---|---|---|---|
Return(%) | -0.78 | -6.84 | 62.67 | 97.39 | 41.79 | 11.14 |
Relative Return to S&P 500(%) | -3.9 | -11.86 | 56.48 | 84.44 | 25.45 | 2.17 |
Robert Nelsen Ownership Network
Ownership Network List of Robert Nelsen
Ownership Network Relation of Robert Nelsen
Robert Nelsen Owned Company Details
What does Codiak BioSciences Inc do?
Who are the key executives at Codiak BioSciences Inc?
Robert Nelsen is the 10 percent owner of Codiak BioSciences Inc. Other key executives at Codiak BioSciences Inc include See Remarks Yalonda Howze , Chief Scientific Officer Sriram Sathyanarayanan , and See Remarks Nicole Barna .
Codiak BioSciences Inc (CDAKQ) Insider Trades Summary
Over the past 18 months, Robert Nelsen made no insider transaction in Codiak BioSciences Inc (CDAKQ). Other recent insider transactions involving Codiak BioSciences Inc (CDAKQ) include a net sale of 61,535 shares made by Douglas E Williams , a net sale of 20,226 shares made by Linda Bain , and a net sale of 17,534 shares made by Sriram Sathyanarayanan .
In summary, during the past 3 months, insiders sold 0 shares of Codiak BioSciences Inc (CDAKQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 129,081 shares of Codiak BioSciences Inc (CDAKQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 129,081 shares.
Codiak BioSciences Inc (CDAKQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
Codiak BioSciences Inc Insider Transactions
Robert Nelsen Mailing Address
Above is the net worth, insider trading, and ownership report for Robert Nelsen. You might contact Robert Nelsen via mailing address: 8755 W. Higgins Road, Suite 1025, Chicago Il 60631.